Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status

Epigenetic Regulation of Foxp3 Expression in Regulatory T Cells by DNA Methylation

(2014) G. Lal et al.   JOURNAL OF IMMUNOLOGY

Immunotherapy of MHC class I-deficient tumors

(2010) Milan Reiniš   Future Oncology

Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2′-deoxycytidine

(2009) Irina Daurkin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Histone deacetylase inhibitors decrease the antigen presenting activity of murine bone marrow derived dendritic cells

(2009) Eun Sun Kim et al.   CELLULAR IMMUNOLOGY

Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells

(2009) Christine Sers et al.   INTERNATIONAL JOURNAL OF CANCER

Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules

(2008) Sara J. Adair et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors

(2008) A. F. Setiadi et al.   CANCER RESEARCH

Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours

(2008) J. Bubenik   CURRENT CANCER DRUG TARGETS

Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead

(2008) Antonello Mai et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

(2008) M Campoli et al.   ONCOGENE